These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 12672770

  • 1. Multiple sclerosis and Epstein-Barr virus.
    Levin LI, Munger KL, Rubertone MV, Peck CA, Lennette ET, Spiegelman D, Ascherio A.
    JAMA; 2003 Mar 26; 289(12):1533-6. PubMed ID: 12672770
    [Abstract] [Full Text] [Related]

  • 2. Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis.
    Levin LI, Munger KL, Rubertone MV, Peck CA, Lennette ET, Spiegelman D, Ascherio A.
    JAMA; 2005 May 25; 293(20):2496-500. PubMed ID: 15914750
    [Abstract] [Full Text] [Related]

  • 3. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study.
    Ascherio A, Munger KL, Lennette ET, Spiegelman D, Hernán MA, Olek MJ, Hankinson SE, Hunter DJ.
    JAMA; 2001 Dec 26; 286(24):3083-8. PubMed ID: 11754673
    [Abstract] [Full Text] [Related]

  • 4. Serologic Response to the Epstein-Barr Virus Peptidome and the Risk for Multiple Sclerosis.
    Cortese M, Leng Y, Bjornevik K, Mitchell M, Healy BC, Mina MJ, Mancuso JD, Niebuhr DW, Munger KL, Elledge SJ, Ascherio A.
    JAMA Neurol; 2024 May 01; 81(5):515-524. PubMed ID: 38497939
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Genetics of immune response to Epstein-Barr virus: prospects for multiple sclerosis pathogenesis.
    Huang J, Tengvall K, Lima IB, Hedström AK, Butt J, Brenner N, Gyllenberg A, Stridh P, Khademi M, Ernberg I, Al Nimer F, Manouchehrinia A, Hillert J, Alfredsson L, Andersen O, Sundström P, Waterboer T, Olsson T, Kockum I.
    Brain; 2024 Oct 03; 147(10):3573-3582. PubMed ID: 38630618
    [Abstract] [Full Text] [Related]

  • 7. Epstein-barr virus and multiple sclerosis risk in the finnish maternity cohort.
    Munger KL, Hongell K, Cortese M, Åivo J, Soilu-Hänninen M, Surcel HM, Ascherio A.
    Ann Neurol; 2019 Sep 03; 86(3):436-442. PubMed ID: 31226219
    [Abstract] [Full Text] [Related]

  • 8. An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study.
    Sundström P, Juto P, Wadell G, Hallmans G, Svenningsson A, Nyström L, Dillner J, Forsgren L.
    Neurology; 2004 Jun 22; 62(12):2277-82. PubMed ID: 15210894
    [Abstract] [Full Text] [Related]

  • 9. Epstein-Barr virus and disease activity in multiple sclerosis.
    Buljevac D, van Doornum GJ, Flach HZ, Groen J, Osterhaus AD, Hop W, van Doorn PA, van der Meché FG, Hintzen RQ.
    J Neurol Neurosurg Psychiatry; 2005 Oct 22; 76(10):1377-81. PubMed ID: 16170080
    [Abstract] [Full Text] [Related]

  • 10. Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel.
    Munger KL, Levin LI, O'Reilly EJ, Falk KI, Ascherio A.
    Mult Scler; 2011 Oct 22; 17(10):1185-93. PubMed ID: 21685232
    [Abstract] [Full Text] [Related]

  • 11. Prevalence of primary versus reactivated Epstein-Barr virus infection in patients with VCA IgG-, VCA IgM- and EBNA-1-antibodies and suspected infectious mononucleosis.
    Nystad TW, Myrmel H.
    J Clin Virol; 2007 Apr 22; 38(4):292-7. PubMed ID: 17336144
    [Abstract] [Full Text] [Related]

  • 12. Investigation of atypical serological profiles for Epstein-Barr virus (EBV).
    Portet Sulla V, Kadi A, Mouna L, Fenaux H, Cechura H, Rafek R, Di Ciccone JL, Warnakulasuriya F, Vauloup-Fellous C.
    J Virol Methods; 2024 Sep 22; 329():115002. PubMed ID: 39067186
    [Abstract] [Full Text] [Related]

  • 13. Evaluation the Architect EBV VCA IgM, VCA IgG, and EBNA-1 IgG chemiluminescent immunoassays to assess EBV serostatus prior transplantation.
    Maylin S, Feghoul L, Salmona M, Herda A, Mercier-Delarue S, Simon F, Legoff J.
    J Med Virol; 2017 Nov 22; 89(11):2003-2010. PubMed ID: 28661055
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Evaluation of Epstein-Barr virus-specific antibodies in Cypriot multiple sclerosis patients.
    Deeba E, Koptides D, Gaglia E, Constantinou A, Lambrianides A, Pantzaris M, Krashias G, Christodoulou C.
    Mol Immunol; 2019 Jan 22; 105():270-275. PubMed ID: 30562647
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up.
    DeLorenze GN, Munger KL, Lennette ET, Orentreich N, Vogelman JH, Ascherio A.
    Arch Neurol; 2006 Jun 22; 63(6):839-44. PubMed ID: 16606758
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A prospective study of Epstein-Barr virus antibodies and risk of non-Hodgkin lymphoma.
    Bertrand KA, Birmann BM, Chang ET, Spiegelman D, Aster JC, Zhang SM, Laden F.
    Blood; 2010 Nov 04; 116(18):3547-53. PubMed ID: 20647565
    [Abstract] [Full Text] [Related]

  • 20. Antibodies to Epstein-Barr virus and MRI disease activity in multiple sclerosis.
    Kvistad S, Myhr KM, Holmøy T, Bakke S, Beiske AG, Bjerve KS, Hovdal H, Løken-Amsrud KI, Lilleås F, Midgard R, Njølstad G, Pedersen T, Benth JŠ, Wergeland S, Torkildsen O.
    Mult Scler; 2014 Dec 04; 20(14):1833-40. PubMed ID: 24842958
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.